<DOC>
	<DOCNO>NCT01140581</DOCNO>
	<brief_summary>Primary Objective : - Evaluate rate Atrial Fibrillation ( AF ) recurrences one month randomization accord different timing initiation dronedarone . Secondary Objective : - Evaluate rate AF recurrences two month randomization . - Assess safety change amiodarone dronedarone - Assess dronedarone safety - Explore dronedarone active metabolite plasma level ( subset country ) - Explore potential Pharmacokinetic ( PK ) interaction dronedarone amiodarone ( subset country )</brief_summary>
	<brief_title>Optimal Timing Dronedarone Initiation After Conversion Patients With Persistent Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Inclusion criterion : Screening : Persistent AF 72 hour ( document ECG take within last 72 hour ) cardioversion , antiarrhythmic treatment anticoagulation treatment indicated opinion Investigator Naive amiodarone treatment last three month QTc Bazett &lt; 500 m 12lead ECG , At least one cardiovascular risk factor ( i.e . age &gt; 70 , hypertension , diabetes , prior cerebrovascular disease leave atrial diameter &gt; = 50 mm Randomization : Outpatient Inpatients ( except patient hospitalized screening period SAE ) Sinus rhythm Effective oral anticoagulation verify International Normalized Ratio/INR ( target &gt; 2 ) QTc Bazett &lt; 500 m PR &lt; 280 m 12lead ECG Completed treatment period amiodarone ( 28 day Â± 2 day ) Exclusion criterion : Screening : Contraindication oral anticoagulation Acute condition know cause AF Permanent AF Paroxysmal AF Bradycardia &lt; 50 bpm 12lead ECG Clinically overt congestive heart failure : New York Heart Association ( NYHA ) class III IV heart failure LVEF &lt; 35 % NYHA class II recent decompensation require hospitalization referral specialized heart failure clinic unstable hemodynamic condition Severe hepatic impairment Previous treatment class I class III antiarrhythmic drug ( include sotalol ) take less one week Previous history amiodarone intolerance toxicity Any contraindication per dronedarone amiodarone label WolffParkinsonWhite Syndrome Previous ablation atrial fibrillation plan ablation next 2 month Contraindicated concomitant treatment : Potent cytochrome P450 ( CYP3A4 ) inhibitor Use drug herbal product prolong QT interval know increase risk Torsades de Pointes Class I III antiarrhythmic drug ( include sotalol ) Randomization : Bradycardia &lt; 50 bpm 12lead ECG Clinically overt congestive heart failure : New York Heart Association ( NYHA ) class III IV heart failure LVEF &lt; 35 % NYHA class II recent decompensation require hospitalization referral specialized heart failure clinic unstable hemodynamic condition Severe hepatic impairment Previous treatment class I class III antiarrhythmic drug ( include sotalol ) take less one week Patient follow contraindicated concomitant treatment mandatory : Potent cytochrome P450 ( CYP3A4 ) inhibitor Use drug herbal product prolong QT interval know increase risk Torsades de Pointes Class I III antiarrhythmic drug ( include sotalol ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>